16. An update of fixed drug eruptions and fixed drug eruptions caused by Trimethoprim - Sulfamethoxazole
Main Article Content
Abstract
This study aimed to provide an update on FDE in general focusing on FDE caused by trimethoprim-sulfamethoxazole. The findings reveal that the most commonly affected age group was over 50 years old, with a mean age of 46. Antibiotics were the most frequent allergens, among which trimethoprim-sulfamethoxazole (Biseptol) accounted for the highest proportion (32.8%). Among patients with genital lesions, males accounted for 85.2%, higher than females (14.8%), p = 0.009. A relationship was also noted between a history of FDE and the time to onset; patients with a history of FDE had a higher proportion of onset within 24 hours compared to those beyond 24 hours (58.8% vs. 41.2%, p < 0.01). Among FDE cases caused by Biseptol, 90.5% had a previous history of FDE, the highest proportion of onset occurred within 24 hours after drug administration (57.1%). FDE associated with Biseptol demonstrated a high rate of mucosal involvements (66.7%), with most patients exhibiting multiple lesions (95.2%). All patients presented with erythematous or hyperpigmented lesions accompanied by itching and burning at the lesion sites.
Article Details
Keywords
Antibiotics, drug eruptions, fixed drug eruption, non-steroidal anti-inflammatory drugs, trimethoprim-sulfamethoxazole
References
2. Patell RD, Dosi RV, Shah PC, Joshi HS. Widespread bullous fixed drug eruption. BMJ Case Rep. 2014; 2014:bcr2013200584. doi:10.1136/bcr-2013-200584.
3. Miah MA, Ahmed SS, Chowdhury SA, Begum F, Rahman SH. Fixed drug eruptions due to cotrimoxazole. Mymensingh Med J MMJ. 2008; 17(2 Suppl):S1-5.
4. Brahimi N, Routier E, Raison-Peyron N, et al. A three-year-analysis of fixed drug eruptions in hospital settings in France. Eur J Dermatol EJD. 2010; 20(4): 461-464. doi:10.1684/ejd.2010.0980.
5. Mahboob A, Haroon TS. Drugs causing fixed eruptions: a study of 450 cases. Int J Dermatol. 1998; 37(11): 833-838. doi:10.1046/j.1365-4362.1998.00451.x.
6. Heng YK, Yew YW, Lim DSY, Lim YL. An update of fixed drug eruptions in Singapore. J Eur Acad Dermatol Venereol JEADV. 2015; 29(8): 1539-1544. doi:10.1111/jdv.12919.
7. Tripathy R, Pattnaik KP, Dehury S, et al. Cutaneous adverse drug reactions with fixed-dose combinations: Special reference to self-medication and preventability. Indian J Pharmacol. 2018; 50(4): 192-196. doi:10.4103/ijp.IJP_760_16
8. Byrd RC, Mournighan KJ, Baca-Atlas M, Helton MR, Sun NZ, Siegel MB. Generalized bullous fixed-drug eruption secondary to the influenza vaccine. JAAD Case Rep. 2018;4(9):953-955. doi:10.1016/j.jdcr.2018.07.013
9. Ozkaya-Bayazit E. Specific site involvement in fixed drug eruption. J Am Acad Dermatol. 2003;49(6):1003-1007. doi:10.1016/s0190-9622(03)01588-3
10. Ozkaya-Bayazit E, Akar U. Fixed drug eruption induced by trimethoprim-sulfamethoxazole: evidence for a link to HLA-A30 B13 Cw6 haplotype. J Am Acad Dermatol. 2001; 45(5): 712-717. doi:10.1067/mjd.2001.117854.
11. Ognongo-Ibiaho AN, Atanda HL. Epidemiological study of fixed drug eruption in Pointe-Noire. Int J Dermatol. 2012; 51 Suppl 1:30-31, 33-35. doi:10.1111/j.1365-4632.2012.05561.x.
12. Nnoruka EN, Ikeh VO, Mbah AU. Fixed drug eruption in Nigeria. Int J Dermatol. 2006; 45(9): 1062-1065. doi:10.1111/j.1365-4632.2006.02912.x.
13. Sharma VK, Dhar S, Gill AN. Drug related involvement of specific sites in fixed eruptions: a statistical evaluation. J Dermatol. 1996; 23(8): 530-534. doi:10.1111/j.1346-8138.1996.tb02646.x.
14. Ahmed AM, Pritchard S, Reichenberg J. A review of cutaneous drug eruptions. Clin Geriatr Med. 2013; 29(2): 527-545. doi:10.1016/j.cger.2013.01.008.
15. Hager JL, Mir MR, Hsu S. Fluoroquinolone-induced generalized fixed drug eruption. Dermatol Online J. 2009; 15(12):8.